Precigen, Inc., (PGEN) is a next generation biopharmaceutical company of gene and cellular therapies. The corefield of research of the companyincludeauto-immune disorders,immune-oncology and infectious diseases. PGEN has several projects in the pipeline contributing to the preclinical and clinical trials of differentimmune-therapies and their commercialization. Some of the focal products of the company include UltraCAR-T, UltraVector, AdenoVerse Immunotherapy and ActoBiotics.
The stock price of PGEN during the regular trading session of December 13, 2021, was reported to be $3.70 with a decline of 3.70%. At the time of writing, the after market also showed a further decrease of 1.35%.
Events and Happenings
On December 13, 2021 Precigen, presented positive interim data at the 63rd ASH Annual Meeting and Exposition from the company’s ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T®. The study took place on patients with severe effects of myelodysplastic syndromes (MDS)andrelapsed or refractory acute myeloid leukemia (AML). The resultsevidenced that PRGN-3006 was welltolerated at multiple dose levelwith no dose-limiting toxicities (DLTs) and no neurotoxicity.
On November 10, 2021 PGEN announced that CEO of Precigen, Helen Sabzevari, participated in the Stifel 2021 Virtual Healthcare Conference held on Wednesday, November 17, 2021.
On November 4, 2021, PGEN announced that the company hosted 2021 R&D Day virtual event and the company’s management presented the clinicaloutcomes. The event showcased clinical progress for company’s AdenoVerse immunotherapy platform, including PRGN-2009 off-the-shelf (OTS) AdenoVerse Immunotherapy, PRGN-2012 OTS AdenoVerse Immunotherapy and UltraCAR-T platform, including PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T, PRGN-3007 UltraCAR-T.
On October 26, 2021, PGEN reported that the Food and Drug Administration (FDA) US had approved the Investigational New Drug (IND) application to initiate the Phase 1/1b clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors. On October 1, 2021, PGEN announced positive data from the Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of patients withrecently started type 1 diabetes (T1D).
On August 9, 2021 PGEN announced second quarter 2021 financial results ended June 30, 2021, which reported the rise in the total revenue of the company from $30.4 million for Q2 2020 to $33.6 million for the same quarter of 2021.
The stock price of PGEN showed a 4% decline from the past week. The company recently presented the positive interim data for their research findings, so the analysts are optimistic that the PGEN stock will make a strong comeback in the market.